Trends of bacterial resistance phenotypes in high-complexity public and private hospitals in Colombia;Tendencias de los fenotipos de resistencia bacteriana en hospitales públicos y privados de alta complejidad de Colombia

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 30, Issue 6, 2011, Pages 627-633

  Rodríguez, Andrea Patricia Villalobos ^a   Ortega, Miguel Hernando Díaz ^a   Garzón, Liliana Isabel Barrero ^a   Vargas, Sandra Milena Rivera ^a   Iguarán, Daibeth Elena Henríquez ^b   Botero, María Virginia Villegas ^c   Restrepo, Carlos Gonzalo Robledo ^d   Castro, Aura Lucía Leal ^e  

^a INSTITUTO NACIONAL DE SALUD   (Colombia)

^b Laboratorio de Salud Pública   (Colombia)

^c CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^d Grupo para el Estudio de la Resistencia a Anti bióticos de Medellín   (Colombia)

^e UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Anti bacterial agents; Colombia; Drug resistance, bacterial; Epidemiologic surveillance; Hospitals

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIAL DISEASE; DISEASE CONTROL; DRUG RESISTANCE; EPIDEMIOLOGY; HOSPITAL SECTOR; PHENOTYPE; PUBLIC HEALTH; SPATIOTEMPORAL ANALYSIS; TREND ANALYSIS;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; COLOMBIA; COMPARATIVE STUDY; CROSS INFECTION; HEALTH SURVEY; HUMAN; MICROBIOLOGY; MORBIDITY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; PHENOTYPE; PRIVATE HOSPITAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; STATISTICS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COLOMBIA; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOSPITALS, PRIVATE; HOSPITALS, PUBLIC; HUMANS; MORBIDITY; PHENOTYPE; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; VANCOMYCIN RESISTANCE;

COLOMBIA;

BACTERIA (MICROORGANISMS); ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84860007568     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/S1020-49892011001200022     Document Type: Article

References (20)

1. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes:mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;15;42(Suppl2):S82-9.
2. Wilson SJ, Knipe CJ, Zieger MJ, Gabehart KM, Goodman JE, Volk HM,et al. Direct costs of multidrug-resistant Acinetobacter baumannii inthe burn unit of a public teaching hospital. Am J Infect Control. 2004;32(6):342-4. (Pubitemid 39348964)
3. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control. 2006;34(5 Suppl 1):S3-10; discussion S64-73.
4. Kaye KS, Engemann JJ, Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am. 2004;18(3):467-511. (Pubitemid 39078726)
5. World Health Organization. World Health Organization: Fifty-firstWorld Health Assembly item 21.3, Emerging and other communicable diseases: Antimicrobial resistance. Ginebra: OMS; 1998. (WHA51.17, agendaitem 21.3).
6. European Centre for disease prevention and control (ECDC). Annualepidemiological report on communicable diseases in Europe. Estocolmo:EDCD; 2010. (Surveillance report: Annual Epidemiological report on communicable diseases in Europe).
7. Organización Mundial de la Salud. Estrategia mundial de la OMS para contener la resistencia a los antimicrobianos. WHO/CDS/CSR/2001.2.
8. McGowan JE. Antibiotic resistance in hospital bacteria: current patterns, modes of appearance or spread and economic impact. Rev Med Microbiol. 1999;2:161-9.
9. Ministerio de la Protección Social. Caracterización de entidades,redes y grupos de investigación en infecciones intrahospitalariasy resistencia bacteriana. [en línea]. Bogotá D.C.: Ministerio de la Protección Social; 2009. Disponible en: http://www.ins.gov. co/?idcategoria=88860 Acceso el 27 de enerode 2011.
10. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, et al.its relationship to extended-spectrum betalactamaseproduction in Klebsiella pneumoniae isolates causing bacteremia. ClinInfect Dis.2000;30(3):473-8.
11. Villegas MV, Correa A, Perez F, Zuluaga T, Radice M, Gutkind G, et al. CTX-M-12 beta-lactamase in a Klebsiella pneumoniae clinical isolate in Colombia. Antimicrob Agents Chemother.2004;48(2):629-31. (Pubitemid 38141730)
12. Villegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M,et al. First detection of the plasmid-mediated class A carbapenemaseKPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006;50(8):2880-2. (Pubitemid 44198721)
13. Ardanuy C, Linares J, Dominguez MA, Hernandez-Alles S, Benedi VJ, Martinez-Martinez L. Outer membrane profiles of clonally related Klebsiella pneumoniae isolates from clinical samples and activities of cephalosporins and carbapenems. Antimicrob Agents Chemother. 1998;42(7):1636-40. (Pubitemid 28311554)
14. Sanders WE Jr, Sanders CC. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev. 1997;10(2):220-41. (Pubitemid 27196669)
15. GREBO - Grupo de Estudio de la Resistencia en Bogotá [internet].Bogotá D.C.: grebo.org;2011. Disponible en: http://www.grebo.org/Acceso el 2 de marzo de 2011.
16. Chong Y, Lee K. Present situation of antimicrobial resistance inKorea. J Infect Chemother. 2000;6(4):189-95. (Pubitemid 32052310)
17. Secretaría Distrital de Salud de Bogotá. Boletín Epidemiológico de Resistencia Bacteriana (SIVIBAC) 2008-2009. [en línea]. Bogotá D.C.: Secretaria Distrital de Salud de Bogotá; 2008. Disponible en: http://www.saludcapitalgov.co/sitios/ VigilanciaSaludPublica/SiteCollectionDocuments/Bolet%C3%ADn%20SIVIBAC%202008%20- %202009.pdf Acceso el 28 de enero de 2011.
18. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 1995;18;273(3):214-9.
19. Serefhanoglu K, Turan H, Timurkaynak FE, Arslan H. Bloodstream infections caused by ESBL-producing E. coli and K. pneumoniae: risk factors for multidrug-resistance. Braz J Infect Dis. 2009;13(6):403-7.
20. Slama TG. Gram-negative antibiotic resistance:there is a price to pay. Crit Care. 2008;12(Suppl 4):S1-7.